On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology. The Nature Biotechnology paper, which suggested CRISPR-Cas9 can produce large genomic deletions, sent CRISPR stocks tumbling Monday, shaving over $530 million in market cap from the companies’ collective value.


Read the full 640 word article

User Sign In